Cysteinyl leukotrienes and 8-isoprostane in exhaled breath condensate of children with asthma exacerbations

Baraldi E; Carraro S; Alinovi R; Pesci A; Ghiro L; Bodini A; Piacentini G; Zacchello F; Zanconato S
June 2003
Thorax;Jun2003, Vol. 58 Issue 6, p505
Academic Journal
BACKGROUND: Cysteinyl leukotrienes (Cys-LTs) and isoprostanes are inflammatory metabolites derived from arachidonic acid whose levels are increased in the airways of asthmatic patients. Isoprostanes are relatively stable and specific for lipid peroxidation, which makes them potentially reliable biomarkers for oxidative stress. A study was undertaken to evaluate the effect of a course of oral steroids on Cys-LT and 8-isoprostane levels in exhaled breath condensate of children with an asthma exacerbation. METHODS: Exhaled breath condensate was collected and fractional exhaled nitric oxide (FE(NO)) and spirometric parameters were measured before and after a 5 day course of oral prednisone (1 mg/kg/day) in 15 asthmatic children with an asthma exacerbation. Cys-LT and 8-isoprostane concentrations were measured using an enzyme immunoassay. FE(NO) was measured using a chemiluminescence analyser. Exhaled breath condensate was also collected from 10 healthy children. RESULTS: Before prednisone treatment both Cys-LT and 8-isoprostane concentrations were higher in asthmatic subjects (Cys-LTs, 12.7 pg/ml (IQR 5.4-15.6); 8-isoprostane, 12.0 pg/ml (9.4-29.5)) than in healthy children (Cys-LTs, 4.3 pg/ml (2.0-5.7), p=0.002; 8-isoprostane, 2.6 pg/ml (2.1-3.0), p<0.001). After prednisone treatment there was a significant decrease in both Cys-LT (5.2 pg/ml (3.9-8.8), p=0.005) and 8-isoprostane (8.4 pg/ml (5.4-11.6), p=0.04) concentrations, but 8-isoprostane levels remained higher than in controls (p<0.001). FE(NO) levels, which fell significantly after prednisone treatment (p<0.001), did not correlate significantly with either Cys-LT or 8-isoprostane concentrations. CONCLUSION: After a 5 day course of oral prednisone there is a reduction in Cys-LT and 8-isoprostane levels in EBC of children with an asthma exacerbation, although 8-isoprostane levels remain higher than in controls. This finding suggests that corticosteroids may not be fully effective in reducing oxidative stress in children with an exacerbation of asthma.


Related Articles

  • Alelic association and functional studies of promoter polymorphism in the leukotriene C4 synthase gene (LTC4S) in asthma. Sayers, I.; Barton, S.; Rorke, S.; Beghé, B.; Hayward, B.; van Eerdewegh, P.; Keith, T.; Clough, J.B.; Ye, S.; Holloway, J.W.; Sampson, A.P.; Holgate, S.T. // Thorax;May2003, Vol. 58 Issue 5, p417 

    Focuses on the allelic association and functional studies of promoter polymorphism in the leukotriene C4 synthase (LTC4S) gene in asthma. Role of LTC4S promoter polymorphism in asthma; Identification of the potential significance of LTC4 synthase as a regulator of the production of cys-LTs in...

  • The Use of Leukotriene Modifying Drugs in Asthma and Other Respiratory Diseases. J.A. Corless; M. Paracha // Current Drug Targets - Inflammation & Allergy;Sep2002, Vol. 1 Issue 3, p271 

    Only rarely in modern medicine is an entirely new class of drug developed. Recently, a number of drugs that act as leukotriene modifiers (LTM's) have been licensed for use in the treatment of asthma. Airway obstruction in asthma has two key components-bronchoconstriction of airway smooth muscle...

  • Citations and Clinicians' Notes: Basic Mechanisms.  // Current Medical Literature: Allergy;2003, Vol. 11 Issue 3, p48 

    Focuses on the expression of the cysteinyl leukotrienes in cultured human bronchial smooth muscle cells exposed to cytokines. Pathogenesis of asthma symptoms and airway remodeling; Enhancement of cellular proliferation; Response of human bronchial smooth muscle cells to the leukotrienes.

  • Zafirlukast shows promise as adjunct to corticosteroids.  // Formulary;Jun98, Vol. 33 Issue 6, p516 

    Reports on study results indicating that daily prophylactic use of the leukotriene receptor blocker zafirkulast (Accolate) as an adjunct to low-dose inhaled corticosteroids improves asthma symptoms and peak flow rates at least as well as doubled corticosteroid use. Dosage given in a...

  • Leukotriene modifiers in the treatment of asthma. Sampson, Anthony; Holgate, Stephen // BMJ: British Medical Journal (International Edition);04/25/98, Vol. 316 Issue 7140, p1257 

    Editorial. Looks at the treatment of asthma with the use of leukotriene modifiers. Reference to leukotriene synthesis inhibitors and cysteinyl leukotriene receptor antagonists, which are the two types of leukotriene modifiers; Detailed information on the two leukotriene modifiers; Relation to...

  • Montelukast beneficial in asthma exacerbations.  // Pulse;10/27/2010, Vol. 70 Issue 32, p9 

    The article discusses a study conducted in Great Britain which suggests the use of leukotriene receptor antagonists during acute asthma exacerbations.

  • Guidelines Update: Where Do the New Therapies Fit in the Management of Asthma? Kemp, J.P. // Drugs;Jun2000 Supplement 1, Vol. 59 Issue 6, p23 

    The new leukotriene (LT) modifiers have been shown to be effective, safe and convenient ‘controller’ medications in patients with asthma. However, their use in asthma is recommended only in the most recent US guidelines, and then only as alternative long term controllers in patients...

  • Antileukotriene Drugs in Childhood Asthma: What is Their Place in Therapy? Selvadurai, H.; Mellis, C. // Pediatric Drugs;Sep/Oct2000, Vol. 2 Issue 5, p367 

    Leukotriene antagonists are a new class of anti-inflammatory drugs which have shown clinical efficacy in the management of asthma. However, their role in paediatric asthma is still unclear. In essence, while there are theoretical reasons as to why leukotriene antagonists would be of use in the...

  • Leukotriene antagonist use questionable in the US.  // PharmacoEconomics & Outcomes News;5/22/2004, Issue 453, p5 

    Provides information on a study regarding the inconsistencies of the use of leukotriene antagonists as initial therapy for asthma with current clinical guidelines in the U.S., as of ay 2004. Analysis of drug use among patients who had received prescriptions for zafirlukast, montelukast and...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics